Real-World Insights into Diacomit Prescribing for Seizures Reported

Real-world insights into how US healthcare providers (HCPs) are using Diacomit (stiripentol; Biocodex, Bedminster, NJ) to treat seizures were presented at the American Epilepsy Society (AES) 2024 Annual Meeting. Results from the study analysis reveal that a significant proportion of patients with Dravet syndrome (DS) are receiving Diacomit without concomitant clobazam and are receiving doses less than the approved recommended dosing of 50 mg/kg/d. Additionally, prescribers are using Diacomit to treat patients without DS. Diacomit is currently approved by the Food and Drug Administration (FDA) as an oral capsule or packet for oral suspension for the treatment of seizures in patients with DS who are receiving clobazam.

The retrospective analysis included all new patients in the United States aged <1 to 53 years who were prescribed ≥1 dose of Diacomit from 2022 to 2024. Researchers assessed patient demographic information, dosing regimens, diagnosis, and concomitant medication use.

• The overall average dose of Diacomit was 38.16 mg/kg/d—significantly less than the approved recommended dosing of 50 mg/kg/d.
• Younger patients received higher doses of Diacomit than older patients.
• 50% of patients who were prescribed Diacomit were not taking concomitant clobazam.
• 39.52% of patients with DS who were prescribed Diacomit received the medication as a 250 mg packet.
• 43.5% of patients without DS who were prescribed Diacomit received 250 mg capsules.

At Diacomit initiation:

• 75% of patients with DS used concomitant clobazam vs 53% of those without DS.
• 37% of patients with DS used concomitant Epidiolex (cannabidiol; Jazz Pharmaceuticals, Dublin, Ireland) vs 20% of those without DS.
• 24% of patients with DS used concomitant Fintepla (fenfluramine; UCB, Smyrna, GA) vs 13% of those without DS.

At Diacomit refill:

• 50% of patients with DS used concomitant clobazam vs 52% of those without DS.
• 24% of patients with DS used concomitant Epidiolex vs 22% of those without DS.
• 16% of patients with DS used concomitant Fintepla vs 20% of those without DS.

The findings demonstrate that, over time, a decreasing percentage of patients with DS treated with Diacomit used concomitant Epidiolex and Fintepla, while this percentage increased for patients without DS.